CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2018—Illumina introduced its NextSeq 550Dx instrument, the company’s second FDA-regulated and CE-IVD-marked next-generation-sequencing system. Illumina also announced that the intended use for the MiSeqDx instrument now includes the use of DNA libraries generated from formalin-fixed, paraffin-embedded tissues.
The NextSeq 550Dx platform includes a diagnostic mode and a research mode, which provide the flexibility to perform clinical research and develop a range of IVD assays on one instrument. For large clinical laboratories, the instrument offers a validated high-throughput platform and will soon provide access to an expanding pipeline of clinical applications in oncology and reproductive health.
Assays that are run on the instrument follow a simple process that includes sequencing and data analysis. The setup of workflows for different applications are fully integrated in NextSeq 550Dx software. The instrument also offers fully integrated onboard analysis software with modular software architecture to support current and future assays.
The expanded intended use of the MiSeqDx instrument enables the development of additional advanced diagnostic products and services at clinical labs by giving clinicians access to information generated on Illumina’s NGS technology.
Illumina, 858-202-4500